NCT05224414 Interpretation Bias as a Mechanism of Treatment Response in OCD
| NCT ID | NCT05224414 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Mclean Hospital |
| Condition | Obsessive-Compulsive Disorder |
| Study Type | INTERVENTIONAL |
| Enrollment | 106 participants |
| Start Date | 2022-03-30 |
| Primary Completion | 2026-08-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 106 participants in total. It began in 2022-03-30 with a primary completion date of 2026-08-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study will conduct a randomized controlled trial of Cognitive Bias Modification for Interpretation (CBM-I) as an augmentation to treatment as usual for obsessive compulsive disorder (OCD). CBM-I is a digital intervention designed to directly manipulate interpretation bias through repeated practice on a training task, thereby inducing cognitive changes in a relatively automatic or implicit manner. Specifically, this study will examine the feasibility, acceptability, and clinical outcomes associated with CBM-I. Adults with obsessive compulsive disorder (OCD) will be recruited from a treatment program for this disorder and participants will be randomly assigned to either receive: 1) up to 12 sessions of CBM-I, or or up to 12 sessions of psychoeducation as a control condition.
Eligibility Criteria
Inclusion Criteria: * 1\) OCD Institute patients * 2\) adults (\> 18 years old) * 3\) able to complete a computer task for 20 minutes * 4\) consent to main OCD Institute study protocol * 5\) primary diagnosis of OCD (as measured by a score of \>16 on the Y-BOCS and a clinical diagnosis of OCD by their treatment team * 6\) score of \>131 on the Obsessive Beliefs Questionnaire-44 at admission \[which is 1 SD above the mean score of the non-clinical sample reported in the original validation paper by the Obsessive Compulsive Cognitions Working Group (2005)\] Exclusion Criteria: * 1\) Currently experiencing acute symptoms of psychosis * 2\) Psychotic disorder diagnosis
Contact & Investigator
Frequently Asked Questions
Who can join the NCT05224414 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Obsessive-Compulsive Disorder. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05224414 currently recruiting?
Yes, NCT05224414 is actively recruiting participants. Contact the research team at mfalkenstein@mclean.harvard.edu for enrollment information.
Where is the NCT05224414 trial being conducted?
This trial is being conducted at Belmont, United States.
Who is sponsoring the NCT05224414 clinical trial?
NCT05224414 is sponsored by Mclean Hospital. The trial plans to enroll 106 participants.